Olmesartan medoxomil/amlodipine

Drugs

Volumn 69, Issue 6, 2009, Pages 717-729

  Sanford, Mark ^a   Keam, Susan J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS OLMESARTAN; CARBAMAZEPINE; DIHYDROPYRIDINE DERIVATIVE; FOSPHENYTOIN SODIUM; HYDROCHLOROTHIAZIDE; ITRACONAZOLE; KETOCONAZOLE; OLMESARTAN; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; RIFAMPICIN; RITONAVIR; SEVIKAR; UNCLASSIFIED DRUG;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; MONOTHERAPY; NONHUMAN; PERIPHERAL EDEMA; REVIEW; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; VERTIGO;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; IMIDAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES; TREATMENT OUTCOME;

EID: 66049134201     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969060-00005     Document Type: Review

References (26)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003 May 14; 289 (18): 2363-9.
2. Whitworth JA. 2003 World Health Organization (WHO) International Society of Hypertension (ISH) statement on management of hypertension (World Health Organization, International Society of Hypertension Writing Group). J Hypertens 2003 Nov; 21 (11): 1983-92.
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007 Jun; 28 (12): 1462-536.
4. Daiichi Sankyo Inc. Marketing approval for Sevikar granted [media release 2008 Nov 13] [online]. Available from URL:http://www.daiichi-sankyo.eu/site-eu/ index.php?node-id=2683 [Accessed 2008 Nov 24].
5. Daiichi Sankyo, Netherlands. Sevikar-: summary of product characteristics [online]. Available from URL: http://www.artsenapotheker.nl/geneesmiddel/ sevikar [Accessed 2009 Mar 23].
6. Daiichi Sankyo Inc. Azor- (amlodipine and olmesartan medoxomil): prescribing information [online]. Available from URL: http://www.fda.gov/cder/ foi/label/2007/022100lbl.pdf [Accessed 2008 Dec 3].
7. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens 2008 Jan; 10 Suppl. 1: 27-32.
8. Scott LJ,McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239-72.
9. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50 (3): 560-86.
10. Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 2007; 67 (9): 1309-27.
11. Martinez-Martin FJ, Macias-Batista A, Rodriguez-Rosas H, et al. Treatment with a combination of olmesartan plus amlodipine vs. olmesartan plus hydrochlorothiazide in hypertensive patients with metabolic syndrome increases insulin sensitivity and adiponectin and reduces inflammation markers [abstract no. PS23/TUE/02]. J Hypertension 2008; 26 Suppl. 1: 331. Plus poster presented at the 18th Scientific Meeting, European Society of Hypertension and the 22nd Scientific Meeting, International Society of Hypertension; 2008 Jun 14-19; Berlin.
12. Rohatagi S, Lee J, Shenouda M, et al. Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. J Clin Pharmacol 2008 Nov; 48 (11): 1309-22.
13. Rohatagi S, Carrothers TJ, Kshirsagar S, et al. Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil. J Clin Pharmacol 2008 Jul; 48 (7): 823-36.
14. Chrysant SG, MelinoM, Karki S, et al. The Combination of Olmesartan Medoxomil and Amlodipine Besylate in Controlling High Blood Pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30 (4): 587-604.
15. VolpeM, Brommer P, Haag U, et al. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Invest 2009 Jan; 29 (1): 11-25.
16. Barrios V, Laies P, Ammentorp B, et al. Olmesartan medoxomil (OLM) plus amlodipine (AML) provides BP reduction and improves BP goal rate attainment in patients (pts) with moderate-to-severe hypertension [abstract no. PS33/Thu/32]. J Hypertens 2008; 26 Suppl.1: 472-73. Plus poster presented at the 18th Scientific Meeting, European Society of Hypertension and the 22nd Scientific Meeting, International Society of Hypertension; 2008 Jun 14-19; Berlin.
17. Chrysant SG, Rhyne J, Melino M, et al. Combination of amlodipine besylate and olmesartan medoxomil significantly reduces blood pressure in patients with hypertension independent of age [abstract no. PS26/Wed/21]. J Hypertens 2008; 26 Suppl. 1: 375. Plus poster presented at the 18th Scientific Meeting, European Society of Hypertension and the 22nd Scientific Meeting, International Society of Hypertension; 2008 Jun 14-19; Berlin.
18. Chrysant SG, Patron A, Karki S, et al. Combination of amlodipine besylate plus olmesartan medoxomil provides greater reductions in seated diastolic and systolic blood pressure compared with monotherapy in men and women [abstract no.PS26/Wed/15]. J Hypertens 2008; 26 Suppl.1: 374. Plus poster presented at the 18th Scientific Meeting, European Society of Hypertension and the 22nd Scientific Meeting, International Society of Hypertension; 2008 Jun 14-19; Berlin.
19. Bakris G, Mion-Bet S, Karki S, et al. Combination of amlodipine besylate and olmesartan medoxomil provides greater reduction in blood pressure compared with monotherapy in subjects with and without diabetes [abstract no.p-12]. J Clin Hypertens 2008 May; 10 (5; Suppl. A): 10.
20. Oparil S, Ramstad D, Melino M, et al. The combination of amlodipine besylate plus olmesartan medoxomil provides numerically greater reductions in blood pressure compared with component monotherapies in race and ethnic subgroups [abstract no. PS26/Wed/14]. J Hypertens 2008; 26 Suppl.1: 373-4. Plus poster presented at the 18th Scientific Meeting, European Society of Hypertension and the 22nd Scientific Meeting, International Society of Hypertension; 2008 Jun 14-19; Berlin.
21. Bakris G, Eads Jr S, Karki S, et al. Does body mass index influence blood pressure reduction among subjects treated with combination of amlodipine besylate and olmesartan medoxomil versus component monotherapy? [abstract no. PS26/Wed/16]. J Hypertens 2008 Suppl.1; 374. Plus poster presented at the 18th Scientific Meeting, European Society of Hypertension and the 22nd Scientific Meeting, International Society of Hypertension; 2008 Jun 14-19; Berlin.
22. Oparil S, Herron J, Melino M, et al. The combination of amlodipine besylate and olmesartan medoxomil safely reduces blood pressure compared with monotherapy in both patients with stage 1 and 2 hypertension [abstract no. PS26/ Wed/22]. J Hypertens 2008; Suppl. 1: 375-6. Plus poster presented at the 18th Scientific Meeting, European Society of Hypertension and the 22nd Scientific Meeting, International Society of Hypertension; 2008 Jun 14-19; Berlin.
23. Oparil S, Sandoval J, Karki S, et al. Combination of amlodipine besylate and olmesartan medoxomil provides greater reduction in blood pressure compared with monotherapy in naive and non-naive subjects [abstract no.PS26/Wed/23]. J Hypertens 2008; 26 Suppl.1: 376. Plus poster presented at the 18th Scientific Meeting, European Society of Hypertension and the 22nd Scientific Meeting, International Society of Hypertension; 2008 Jun 14-19; Berlin.
24. Chrysant SG, Melino M, Karki S, et al. Long term efficacy and safety of amlodipine besylate and olmesartan medoxomil in achieving BP thresholds in patients with mild to severe hypertension [abstract no. PS26/Wed/29]. J Hypertens 2008 26 Suppl. 1: 377. Plus poster presented at the 18th Scientific Meeting, European Society of Hypertension and the 22nd Scientific Meeting, International Society of Hypertension; 2008 Jun 14-19; Berlin.
25. Chrysant SG, Oparil S, Bakris G, et al. Combination of amlodipine plus olmesartan medoxomil (OM) is effective and safe with long term dosing while treating patients (pts) to blood pressure goal [abstract no. PS26/Wed/17]. J Hyper tens 2008; 26 Suppl. 1: 374. Plus poster presented at the 18th Scientific Meeting, European Society of Hypertension and the 22nd Scientific Meeting, International Society of Hypertension; 2008 Jun 14-19; Berlin.
26. Brommer P, Laeis P, Ammentorp B, et al. Olmesartan medoxomil plus amlodipine is well tolerated in patients with moderate-to-severe hypertension [abstract no. PS33/Thu/33]. J Hypertens 2008; 26 Suppl.1: 473. Plus poster presented at the 18th Scientific Meeting, European Society of Hypertension and the 22nd Scientific Meeting,International Society of Hypertension; 2008 Jun 14-19; Berlin.